

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Jerry W. McLarty, PhD		POSITION TITLE Professor	
eRA COMMONS USER NAME (credential, e.g., agency login) jmclarty		Director Cancer Prevention and Control LSU Feist-Weiller Cancer Center	
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.)			
INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YY	FIELD OF STUDY
University of Houston, Houston TX	B.S.	06/68	Mathematics
University of Houston	M.S.	12/70	Computer Science
University of Texas Graduate School of Biomedical Sciences, Houston TX	Ph.D.	06/76	Biomedical Sciences (Biomathematics)

A. Personal Statement

My career experience in cancer prevention clinical trials and data analysis has qualified me to participate in this study. I have over 20 years experience in the design, conduct and analysis of clinical trials and epidemiological research. As director of Cancer Prevention and Control, I am involved in many studies, including translational research, clinical trials and community intervention. I am experienced in study design and analysis, for laboratory, animal, clinical and epidemiological research. Many of my projects involve underserved and disparate populations. I have been involved in NCI grant funding concerning disparities for much of my career. My present research activities are focused on exploring survival disparities between races, and different socioeconomic groups. My colleagues and I have found that there are significant differences in survival in cancer patients with and without health insurance; this is a surprising finding in our cancer patients who supposedly receive the same care by the same clinical teams regardless of insurance status or ability to pay. Future work will concentrate on exploring the underlying reasons for this strong insurance effect. For the past 11 years, I have been director of a free cancer screening program for uninsured and under-insured patients, the majority of whom are African American. We have seen this program grow from a single hospital-based clinic to include two mobile mammography units which travel to underserved rural and urban sites throughout north Louisiana. Currently, we routinely hold clinics in 22 parishes and are in the process of expanding our operations to the Delta Region of northeast Louisiana. This will add 11 more parishes to our coverage area. The Delta Region is one of the poorest, most underserved regions of the state. These screening programs are done in conjunction with regional and local support in the various communities. In addition to screening, the programs provide to access to patients for educational efforts and other cancer studies. I have been involved as a co-investigator in a NIH funded screening program to test the effect of Health Literacy training on cancer screening rates in Federally Qualified Health Centers.

B. Positions and Honors

ACADEMIC APPOINTMENTS

- 1976 - 1978 Assistant Epidemiologist (Biomathematician), Assistant Professor of Epidemiology, Department of Epidemiology and Biomathematics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, Texas
- 1979 - 1999 Chairman, Department of Epidemiology/Biomathematics, The University of Texas Health Center at Tyler, Tyler, Texas
- 1986 - 2002 Professor of Epidemiology/Biomathematics, The University of Texas Health Center at Tyler, Tyler, Texas
- 1979 - 2002 Acting Director, Tyler Asbestos Workers Program, The University of Texas Health Center at Tyler, Tyler, Texas

2002 - Present Professor of Medicine, Director Cancer Prevention and Control, Feist-Weiller Cancer Center, LSU Health Sciences Center Shreveport, Louisiana.

Honors and Activities

Society of Sigma Xi, 1970.

Legislative Task Force on Cancer in Texas, 1981-1989 ,Consulting Epidemiologist

National Cancer Advisory Board: Invited Speaker, 1986.

NIH Safety & Occupational Health study section from July 2, 1992 to June 30, 1996.

NIH SNEM (now named EPIC) Study Section, August 1999- 2002.

Multiple Ad Hoc NIH review panelist. 1980 – present including National Center for Minority and Health Disparities (NCMHD) RIMI (P20) Review Panel Member

Editorial board member for The American Journal of Physiology: Lung Cellular and Molecular Physiology. January 1994 to December 1996.

International Society for Nutrition and Cancer (ISNAC): Executive Committee Member 1989 - 1994.

Visiting Scientist, Institute for Epidemiologic Research, University of Bergen, Bergen Norway, 1998.

Visiting Lecturer in Biostatistics, University of Zulia, Maracaibo, Venezuela, 1998, 1999.

Louisiana Tobacco Prevention and Cessation Program, Steering Committee: 2002-present.

Louisiana Cancer Control Planning, Executive Committee, Chair Prevention and Early Detection Committee: Jan. 2003-present.

Teaching

2002-present Cancer Epidemiology for medical students and Fellows, Biostatistics for graduate students

2007-present FACTTS Critical Appraisal of the literature for 4th year medical students

State Committees

2003 – 2003 Tobacco Free Living, Steering Committee Member

2003 – present Louisiana Cancer Control Partnership, Co-chair early detection workgroup

C. Publications Most Relevant to the current application

1. Wu and **J. McLarty**. Neural Networks and Genome Informatics. Computational Molecular Biology Book Series, Series Editor A. Konopka. Elsevier Science, Ltd. July 2000.
2. **McLarty, J.**, Wu, C.H. Neural networks. Nature's Encyclopedia of the Human Genome. June 2003 (Invited chapter). Also in Wiley Interscience Encyclopedia of Life Sciences, July 2006.
3. **McLarty, J.W.** How many subjects are required for a study? Clinical Pharmacy, Vol. 7, September, 1988.
4. C. Wu and **J. McLarty**. Neural Networks and Genome Informatics. Computational Molecular Biology Book Series, Series Editor A. Konopka. Elsevier Science, Ltd. July 2000.
5. Shi R, Yu H, **McLarty J**, Glass J. Insulin-Like Growth Factor-I and Breast Cancer : A Meta-Analysis. Int J Cancer. 2004 Sep 1;111(3):418-23.
6. **Jerry McLarty**, Runhua Shi. Prostate cancer in Louisiana: different than expected. Louisiana Morbidity and Mortality Report, Vol. 15, #6, Nov.-Dec. 2004.
7. Ali IU, Xiao Z, Malone W, Smith M, Conrads TP, Veenstra TD, Greenwald P, Luke BT, **McLarty JW**. Plasma proteomic profiling: search for lung cancer diagnostic and early detection markers. Oncol Rep. 2006 May;15(5):1367-72. PMID: 16596212
8. Banks, Shi, **McLarty**, et al. ACCP Consensus Statement on the Respiratory Health Effects of Asbestos: Results of a Delphi Study. Chest 2009;135;1619-1627

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

9. Krishnan P, Yan KJ, Windler D, Tubbs J, Grand R, Li BD, Aldaz M, **McLarty J**, Kleiner-Hancock HE. Citrus auraptene suppresses cyclin D1 and significantly delays N-methyl nitrosourea induced mammary carcinogenesis in female Sprague-Dawley rats. *BMC Cancer*. 2009 Jul 29;9(1):259. PMC2724550.
10. **McLarty J**, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. *Cancer Prevention Research* 2009 Jul;2(7)673-82.
11. Adegboyega, P.A., Rodriguez S., **McLarty, J**. Stromal expression of actin is a marker of aggressiveness in basal cell carcinoma. *Hum Pathol*. 2010 Aug;41(8):1128-37.
12. Becks L, Prince M, Burson H, Christophe C, Broadway M, Itoh K, Yamamoto M, Mathis M, Orchard E, Shi R, **McLarty J**, Pruitt K, Zhang S, Kleiner-Hancock HE. Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12 dimethylbenz[a]anthracene. *BMC Cancer*. 2010 Oct 8;10:540. PMC2964634.
13. Clark C, Shah S, Herman-Ferdinandez L, Ekshyyan O, Abreo F, Rong X, **McLarty J**, Lurie A, Milligan EJ, and Nathan CO. Teasing out the best molecular marker in the AKT/MTOR pathway in HNSCC patients. *Laryngoscope*. 2010 Jun;120(6):1159-65.PMC2997737
14. Kumar, NB, Crocker T, Smith T, Connors S, Pow-Sang J, Spiess PE, Egan K, Quinn G, Schell M, Sebti S, Kazi A, Chuang T, Salup R, Helal M, Zagaja G, Trabulsi E, **McLarty J**, Fazili T, Williams CR, Schreiber F & Anderson K. Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. *Contemp Clin Trials*. 2012 Mar;33(2):279-85. PMC3268882.
15. Shi R, Mills G, **McLarty J**, Burton G, Shi Z, Glass J. Commercial Insurance Triples Chances of Breast Cancer Survival in a Public Hospital. *Breast J*. 2013 Nov-Dec;19(6):664-7. PubMed - in process.

D. Research Support

Current Research Support

U10CA128567

08/01/2007-05/31/2015

NIH-NCI

LSUHSC-Shreveport Feist-Weiller Cancer Center MBCCOP

The Feist-Weiller Cancer Center (FWCC) Minority-Based Community Clinical Oncology Program (MB-CCOP) aims to provide increased access to state-of-the-art cancer prevention care, and control through NCI-sponsored clinical trials to the minority and indigent populations in the northwestern section of La., and throughout the state of Louisiana.

Role: Co-Investigator

Komen Foundation (Shreveport-Bossier Komen Foundation Affiliate)

2003 - present

Partners in Wellness

The Feist-Weiller Cancer Center has an established health care screening program designed for early detection and disease prevention in underserved populations. The highly successful program, called Partners in Wellness, checks for hypertension, cervical cancer, prostate cancer, colon cancer and breast cancer.

Role: Principal Investigator

Health Resources and Services Administration

2009 – present

Building Health Communities.

A HRSA-supported grant to increase cancer screening in disadvantaged rural communities.

Role: Co-Investigator

Tobacco Free Living

2006 - present

Program Director/Principal Investigator (Last, First, Middle): Ochoa, Augusto C.

A state-wide program that addresses tobacco use in Louisiana on many fronts: prevention, education, cessation, research and advocacy.

Role: Regional Director

Early Detection and Prevention Task Force for the Louisiana Cancer Control Plan

Louisiana Breast and Cervical Health Program

(Louisiana's part of the National Breast and Cervical Early Detection Program)

This program provides the prevention of cancer through tobacco control and improved nutrition and the early detection of cancer through increased access to screening tests.

Role: Northwest LA Regional Director

The Rapides Foundation

2009 - present

Breast and cervical cancer screening in North Central Louisiana

Provides women throughout central Louisiana will be able to receive free breast and cervical cancer screenings offered by Partners in Wellness, a cancer screening program of the Feist-Weiller Cancer Center at LSU Health Sciences Center at Shreveport.

Role: Principal Investigator

Circle K Giving Program

2011 – present

Circle K in North Louisiana has chosen to support the free screening program, Partners in Wellness, to save lives by early detection. Their mobile mammography vehicle delivers free care throughout much of Louisiana where Circle K customers live.

Role: Director

Completed Research Support

R21CA149761 Kleiner (PI)

09/20/2011-08/31/2013

NIH-NCI

Targeting Multiple Skin Cancer Pathways Using Citrus Auraptene And ATRA

Our overall hypothesis is that the ATRA + AUR combination is more effective than either agent alone due to the ability of ATRA to suppress Stat3 signaling, and AUR to suppress the NF- κ B pathway and other pathways.

Role: Consultant

R01CA115869

09/27/2007-07/31/2013

NIH-NCI

Health Literacy Intervention and Cancer Screening

The goals of this study were to: 1) test the effectiveness of a clinic-wide, health literacy (HL) intervention to improve initial and repeat use of colorectal (CRC) and breast cancer screening among eligible patients at Federally Qualified Health Centers (FQHCs) and 2) compare the effectiveness of the HL intervention, with and without a Prevention Nurse Case Manager (PNCM), on the screening rates of FQHC patients.

Role: Co-investigator

R01CA12060-01A1

12/01/2007-05/31/2012

NIH-NCI

Phase II, Randomized, Double-blind, Multi-centered Study of Polyphenon E in Men with High-grade Prostatic Intraepithelial Neoplasia (HGPIIN)

This clinical study is a Phase II, randomized, double-blinded, placebo-controlled trial in men 30-80 years of age with biopsy proven HGPIIN and no evidence of prostate cancer, prostatitis or urinary tract infection.

Role: Co-investigator, P.I. LSU Site.

Blue Cross-Blue Shield of Louisiana

01/01/2009-12/31/2012

Fuel support for the mobile vehicle.